false
0001766140
0001766140
2024-05-13
2024-05-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 13, 2024
Unicycive Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-40582 |
|
81-3638692 |
(State or other jurisdiction
of incorporation or organization) |
|
(Commission File Number) |
|
IRS Employer
Identification No.) |
4300 El Camino Real, Suite 210
Los Alto, CA 94022
(Address of principal executive offices)
Registrant’s telephone number, including
area code: (650) 351-4495
(Former name or former address, if changed since
last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class: |
|
Trading
Symbol(s) |
|
Name of each exchange on which registered: |
Common Stock |
|
UNCY |
|
Nasdaq Capital Market |
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written
communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging
growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 Results of Operations and Financial Conditions.
On May 13, 2024, Unicycive Therapeutics, Inc. issued
a press release announcing its financial results for the three months ended March 31, 2024 and provided a business update. A copy of the
press release is furnished as Exhibit 99.1 to this Form 8-K.
The information disclosed under this Item 2.02,
including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document
pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing.
Item 9.01. Financial Statements and Exhibits
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: May 13, 2024
|
UNICYCIVE THERAPEUTICS, INC. |
|
|
|
By: |
/s/ Shalabh Gupta |
|
|
Shalabh Gupta |
|
|
Chief Executive Officer |
2
Exhibit 99.1
![](https://www.sec.gov/Archives/edgar/data/1766140/000121390024042338/ex99-1_001.jpg)
Unicycive Announces
First Quarter 2024 Financial Results and Provides Business Update
–
On Track to Provide Topline Data from the Ongoing Pivotal Clinical Trial with Oxylanthanum Carbonate (OLC) in Q2 2024 –
–
Multiple Presentations on OLC and UNI-494 at Prominent, Upcoming Medical Meetings –
LOS ALTOS, Calif., May
13, 2024 – Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”),
a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results
for the three months ended March 31, 2024, and provided a business update.
“This is an exciting
time for Unicycive as we progress towards the conclusion of our pivotal clinical trial for our lead asset oxylanthanum carbonate (OLC),”
said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. “The trial is evaluating the tolerability, safety, and pharmacokinetics
of clinically effective doses of OLC in patients with chronic kidney disease (CKD) on dialysis and it remains on track with topline data
expected later this quarter. If approved, OLC may provide a meaningful improvement in the quality of life for CKD patients on dialysis
with hyperphosphatemia by reducing the pill burden volume by more than 4-fold compared to the most prescribed phosphate binder1.”
Dr. Gupta, continued,
“We are also developing UNI-494 for the prevention of delayed graft function (DGF) after kidney transplantation and other conditions
related to acute kidney injury. This is an important indication as DGF is one of the most serious complications resulting from kidney
transplantation. UNI-494 is advancing through the multiple ascending dose (MAD) portion of its Phase 1 study, and we expect to complete
the trial and report the full results in the second half of this year.”
“A priority for
us in 2024 is expanding awareness of our programs within the medical and scientific communities. This month we will be presenting important
data on both OLC and UNI-494 at two of the most prominent, global nephrology meetings hosted by the National Kidney Foundation and the
European Renal Association. We look forward to providing updates on our programs at these events for all of our stakeholders,” concluded
Dr. Gupta.
Key Highlights
● | Topline
data expected in the second quarter of 2024 from the pivotal clinical trial of OLC in chronic
kidney disease (CKD) patients on dialysis with hyperphosphatemia. |
● | Multiple
presentations related to OLC and UNI-494 will be presented at the National Kidney Foundation
(NKF) Spring Clinical Meeting (May 14-18) and the 61st European Renal Association
(ERA) Congress (May 23-26). Among these presentations, a poster titled “Renal Dietitians
Perceive Phosphate Binder and Low Phosphorus Diet Non-Compliance as Top Reasons for Above
Target Serum Phosphorus Concentrations”, by lead author Kathleen M. Hill Gallant from
the University of Minnesota-Twin Cities was among the top-rated submissions to the NKF Spring
Clinical Meeting. The poster reports on the findings from a survey of 100 renal dietitians
on factors contributing to patient non-compliance to phosphate binder therapy and the most
appealing features of Oxylanthanum Carbonate, if approved. |
● | Completed
enrollment in the open-label, single-arm, multicenter, multidose pivotal clinical trial
with OLC, a next-generation lanthanum-based phosphate binding agent utilizing proprietary
nanoparticle technology being developed to treat hyperphosphatemia in patients with CKD on
dialysis. |
● | Granted
orphan drug designation (ODD) by the FDA to UNI-494 for the prevention of DGF in kidney transplant
patients. ODD may provide certain tax credits for qualified clinical trials, exemption of
user fees, and the potential for seven years of market exclusivity after approval. UNI-494
is a cytoprotective agent that elicits an ischemic preconditioning effect by activating KATP channels
in mitochondria to restore cellular function. |
● | Presented
new data demonstrating statistically significant results for UNI-494 in a preclinical model
of DGF at the 29th International Conference on Advances in Critical Care
Nephrology AKI and CRRT 2024. The data provides additional evidence that UNI-494 may be a
valuable asset for prevention of DGF and other conditions related to acute kidney injury. |
● | Successfully
completed the single ascending dose (SAD) portion of the Company’s ongoing Phase 1
clinical trial in UNI-494. UNI-494 was well-tolerated up to 160 mg administered as a single
dose and was chosen as the go-forward dose based on promising safety, tolerability, and pharmacokinetic
data. In the multiple ascending dose (MAD) portion of the study, 80 mg is now being administered
twice-a-day to trial participants. |
● | Completed
a private placement with new and existing healthcare institutional investors that generated
$50 million in gross proceeds to Unicycive. |
Financial Results
for the Quarter Ended March 31, 2024
Licensing Revenues: There
were no licensing revenues recorded for the quarter ended March 31, 2024. Licensing revenues of approximately $0.7 million were recorded
in the three months ended March 31, 2023, due to an upfront payment for a licensing agreement entered into with Lotus International PTE
Ltd.
Research and development
(R&D) Expenses: R&D expenses were $6.8 million for the three months ended March 31, 2024, compared to $3.0 million for the three
months ended March 31, 2023. The increase in research and development expenses was primarily due to one time costs related to the OLC
clinical trial.
General and Administrative
(G&A) Expenses: G&A expenses were $2.4 million for the three months ended March 31, 2024, compared to $1.8 million for the three
months ended March 31, 2023. The increase in general and administrative expenses was primarily due to an increase in non-cash stock compensation costs.
Other Income (Expenses):
Other income (expenses) was $11.8 million for the three months ended March 31, 2024, compared to $10.4 million for the three months ended
March 31, 2023. The increase was due primarily to a $11.8 million change in fair value of our warrant liability.
Net Loss: Net loss attributable
to common stockholders for the three months ended March 31, 2024 was $21.2 million, or $0.61 per share of common stock, compared to a
net loss of $14.8 million, or $0.97 per share of common stock, for the three months ended March 31, 2023. This increase was attributable
primarily to increased drug development costs and the change in fair value of our warrant liability.
Cash Position: As of March 31, 2024, cash and
cash equivalents totaled $48.9 million. The Company believes that it has sufficient resources to fund planned operations into 2026.
About Unicycive Therapeutics
Unicycive Therapeutics is a biotechnology company
developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational
phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494
is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. For
more information, please visit Unicycive.com and follow us on LinkedIn and YouTube.
Forward-looking
statements
Certain
statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These
statements may be identified using words such as “anticipate,” “believe,” “forecast,” “estimated”
and “intend” or other similar terms or expressions that concern Unicycive’s expectations, strategy, plans or intentions.
These forward-looking statements are based on Unicycive’s current expectations and actual results could differ materially. There
are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These
factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results
of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due
to unexpected side effects or other safety risks that could preclude approval of our product candidates; risks related to business interruptions
which could seriously harm our financial condition and increase our costs and expenses; dependence on key personnel; substantial competition;
uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure to obtain FDA clearances
or approvals and noncompliance with FDA regulations. Actual results may differ materially from those indicated by such forward-looking
statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described
more fully in the section entitled ‘Risk Factors’ in Unicycive’s Annual Report on Form 10-K for the year ended December
31, 2023, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this
press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward-looking statement,
whether as a result of new information, future events or otherwise.
| 1 | Sprague,
et al, “High Phosphate-Binding Capacity of Oxylanthanum Carbonate with a Low Medication
Volume: Comparison with Commercially Available Phosphate Binders”, American Journal
of Nephrology, September 2023 |
Investor Contact:
ir@unicycive.com
(650) 900-5470
SOURCE: Unicycive Therapeutics, Inc.
--Tables to Follow--
Unicycive Therapeutics, Inc.
Balance Sheets
(In thousands, except for share and per share
amounts)
| |
As of | | |
As of | |
| |
December 31, | | |
March 31, | |
| |
2023 | | |
2024 | |
| |
| | |
(Unaudited) | |
Assets | |
| | |
| |
Current assets: | |
| | |
| |
Cash and cash equivalents | |
$ | 9,701 | | |
$ | 48,930 | |
Prepaid expenses and other current assets | |
| 3,698 | | |
| 2,746 | |
Total current assets | |
| 13,399 | | |
| 51,676 | |
Right of use asset, net | |
| 766 | | |
| 686 | |
Property, plant and equipment, net | |
| 26 | | |
| 23 | |
Total assets | |
$ | 14,191 | | |
$ | 52,385 | |
| |
| | | |
| | |
Liabilities, mezzanine equity, and stockholders’ deficit | |
| | | |
| | |
Current liabilities: | |
| | | |
| | |
Accounts payable | |
$ | 839 | | |
$ | 1,240 | |
Accrued liabilities | |
| 3,234 | | |
| 3,550 | |
Dividends Payable | |
| - | | |
| 208 | |
Warrant liability | |
| 13,134 | | |
| 24,941 | |
Operating lease liability - current | |
| 327 | | |
| 343 | |
Total current liabilities | |
| 17,534 | | |
| 30,282 | |
Operating lease liability – long term | |
| 466 | | |
| 372 | |
Total liabilities | |
| 18,000 | | |
| 30,654 | |
Commitments and contingencies (Note 8) | |
| | | |
| | |
Mezzanine equity: | |
| | | |
| | |
Series B-1 preferred stock, $0.001 par value per share – zero shares authorized at December 31, 2023, and 50,000 shares authorized at March 31, 2024; zero shares outstanding at December 31, 2023, and 50,000 shares outstanding at March 31, 2024 | |
| | | |
| 46,187 | |
Stockholders’ deficit: | |
| | | |
| | |
Series A-2 Prime preferred stock, $0.001 par value per share – 43,649 shares authorized at December 31, 2023, and 21,388 shares authorized at March 31, 2024; 43,649 shares outstanding at December 31, 2023, and 19,992 shares outstanding at March 31, 2024 | |
| - | | |
| - | |
Preferred stock: $0.001 par value per share—9xxxxxx shares authorized at December 31, 2023, and March 31, 2024, respectively; zero shares issued and outstanding at December 31, 2023, and March 31, 2024 | |
| - | | |
| - | |
Common stock, $0.001 par value per share – 200,000,000 shares authorized at December 31, 2023, and March 31, 2024; 34,756,049 shares issued and outstanding at December 31, 2023, and 37,606,630 shares issued and outstanding at March 31, 2024 | |
| 35 | | |
| 37 | |
Additional paid-in capital | |
| 60,697 | | |
| 61,011 | |
Accumulated deficit | |
| (64,541 | ) | |
| (85,504 | ) |
Total stockholders’ deficit | |
| (3,809 | ) | |
| (24,456 | ) |
Total liabilities and stockholders’ deficit | |
$ | 14,191 | | |
$ | 52,385 | |
Unicycive Therapeutics, Inc.
Statements of Operations
(In thousands, except for share and per share
amounts)
(Unaudited)
| |
Three Months Ended March 31, | |
| |
2023 | | |
2024 | |
| |
| | |
| |
Licensing revenues: | |
$ | 675 | | |
$ | - | |
| |
| | | |
| | |
Operating expenses: | |
| | | |
| | |
Research and development | |
| 3,030 | | |
| 6,813 | |
General and administrative | |
| 1,847 | | |
| 2,391 | |
Total operating expenses | |
| 4,877 | | |
| 9,204 | |
Loss from operations | |
| (4,202 | ) | |
| (9,204 | ) |
Other income (expenses): | |
| | | |
| | |
Interest income | |
| 14 | | |
| 69 | |
Interest expense | |
| (12 | ) | |
| (20 | ) |
Change in fair value of warrant liability | |
| (10,375 | ) | |
| (11,808 | ) |
Total other income (expenses) | |
| (10,373 | ) | |
| (11,759 | ) |
Net loss | |
| (14,575 | ) | |
| (20,963 | ) |
Deemed dividend to Series A-1 preferred stockholders | |
| (192 | ) | |
| - | |
Dividend to Series B preferred stockholders | |
| - | | |
| (208 | ) |
Net loss attributable to common stockholders | |
$ | (14,767 | ) | |
$ | (21,171 | ) |
Net loss per share attributable to common stockholders, basic and diluted | |
$ | (0.97 | ) | |
$ | (0.61 | ) |
Weighted-average shares outstanding used in computing net loss per share, basic and diluted | |
| 15,232,406 | | |
| 34,912,692 | |
-5-
v3.24.1.1.u2
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Grafico Azioni Unicycive Therapeutics (NASDAQ:UNCY)
Storico
Da Gen 2025 a Feb 2025
Grafico Azioni Unicycive Therapeutics (NASDAQ:UNCY)
Storico
Da Feb 2024 a Feb 2025